Open an account

NuCana

NCNA · NASDAQ

$0.9853+$0.0253 (+2.64%)TodayMarket closed ·
Prev close $0.96

About NCNA

NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Employees
11
Headquarters
Edinburgh
Listed
Sep 28, 2017
Sector
Health Care
Industry
Biotechnology
Website
nucana.com

NCNA key statistics

Market cap
4.14M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
250.20K
Volume
27.10K
Open price
$0.97
High today
$1.02
Low today
$0.9604
52 Week high
$4.55
52 Week low
$0.9484

NuCana (NCNA) at a glance

As of Oct 23, 2026, NuCana (NCNA) shares are priced at $0.9853, giving the company a market cap of 4.14M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.9604 and $1.02. The current price is 2.6% above the day's low and 3.4% below its high.

Volume so far is 27.10K shares, below the average of 250.20K shares a day.

Over the past year NuCana has ranged from $0.9484 to $4.55, and now sits 1% of the way up that range.

NuCana met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q3 FY24 it reported -$350.00 per share against an estimate of -$545.51.

NCNA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 29.8% on average.

  1. Q4 FY22: reported -$1,450.00 per share against an estimate of -$647.64
  2. Q1 FY23: reported -$750.00 per share against an estimate of -$561.00
  3. Q2 FY23: reported -$500.00 per share against an estimate of -$656.68
  4. Q3 FY23: reported -$650.00 per share against an estimate of -$511.83
  5. Q4 FY23: reported -$700.00 per share against an estimate of -$522.30
  6. Q1 FY24: reported -$650.00 per share against an estimate of -$564.79
  7. Q2 FY24: reported -$600.00 per share against an estimate of -$369.08
  8. Q3 FY24: reported -$350.00 per share against an estimate of -$545.51

NCNA news

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Avi Kapoor

    AST SpaceMobile, SBC Medical Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Avi Kapoor

    US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results

  • 12 Health Care Stocks Moving In Friday's Intraday Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.